Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
Jesús García-DonasGuillermo de VelascoRodrigo MadurgaJesús ChamorroDiana RoseroOlatz EtxanizJose Luis Pérez-GraciaÁlvaro PintoDiego CachoMaría BarbaPablo BorregaMartín LázaroLaura RodriguezLaura VillalobosLourdes GarcíaAndrés CuellarMaría Pilar Solís-HernándezAmalia GonzálezCristina PernautJuan Francisco Rodríguez-MorenoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy.